We can’t show the full text here under this license. Use the link below to read it at the source.
Optimal duration of risperidone or olanzapine adjunctive therapy to mood stabilizer following remission of a manic episode: A CANMAT randomized double-blind trial
Best length of risperidone or olanzapine added to mood stabilizers after recovery from a manic episode: A controlled clinical trial
AI simplified
Abstract
A 52-week trial with 159 patients found that discontinuing atypical antipsychotic treatment after 24 weeks significantly prolonged the time to mood episode relapse compared to stopping at the beginning.
- Continuing risperidone or olanzapine treatment for 52 weeks resulted in an average weight gain of 3.2 kg.
- Patients who stopped antipsychotic treatment at 24 weeks experienced a similar relapse rate to those who continued for 52 weeks.
- There was a significant difference in relapse risk based on the type of antipsychotic: olanzapine showed a potential benefit, while risperidone did not.
- The relapse risk was lower for the 24-weeks group compared to the 0-weeks group, with a hazard ratio of 0.53.
- The potential benefits of continuing olanzapine beyond 24 weeks are uncertain and should be balanced against the risk of weight gain.
AI simplified
Key numbers
0.53
Increase in Time to Mood Episode
Hazard ratio comparing 24-weeks vs. 0-weeks group
3.2 kg
Average Weight Gain
Weight change in the 52-weeks group